YHP2407

YHP2407 is a pharmaceutical product developed by Yuhan Corporation and studied in a Phase 1, randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to evaluate its bioequivalence to YHR2502 in healthy volunteers. The study enrolled 40 healthy subjects and assessed pharmacokinetic similarity between the two oral drugs. The trial was conducted in South Korea and was completed in 2025. The specific active ingredient, mechanism of action, and therapeutic indication of YHP2407 have not been disclosed publicly in the available data. The trial focused on healthy volunteers, so clinical use or further indications are currently undocumented[1][2][3][5][7].